Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04984551
Other study ID # 2019-0462
Secondary ID NCI-2020-0607420
Status Recruiting
Phase N/A
First received
Last updated
Start date August 24, 2020
Est. completion date December 31, 2026

Study information

Verified date February 2024
Source M.D. Anderson Cancer Center
Contact Sriram Yennu
Phone 713-792-6085
Email syennu@mdanderson.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial investigates the experience and satisfaction of care in patients with cancer that has spread to other places in the body (advanced) and their caregivers living in underserved areas of Kenya, Nigeria, Ghana, South Africa, India and Ethiopia as part of Project Extension for Community Healthcare Outcomes (ECHO). Project ECHO is a model of medical education and care management that empowers clinicians to provide better care to more people where they live. Understanding the experiences and satisfaction of patients and caregivers may help improve healthcare workforce capacity and increase access to specialty care for the world's rural and underserved populations.


Description:

PRIMARY OBJECTIVE: I. To evaluate the effects of Project ECHO on patient-reported quality of life (QOL) (as assessed by the change in Functional Assessment of Cancer Illness Therapy FACT-General [G]) in seriously ill patients of providers receiving ECHO model-based comprehensive educational and telementoring intervention (ECHO-Palliative Care, or ECHO-PCT). SECONDARY/EXPLORATORY OBJECTIVES: I. To examine the effects of ECHO-PCT on patients' symptom distress as assessed by the Edmonton Symptom Assessment Scale (ESAS), Symptom Distress Scores (SDS), as well as patient and caregiver experience and satisfaction as assessed by the FAMCARE-P 16-item (16)-patient and FAMCARE-caregiver questionnaires. II. To explore the effects of ECHO-PCT on providers' efficacy in, knowledge of, and competence to deliver Palliative Care to Patients with serious life limiting illness, as well as their satisfaction with providing Palliative Care services as assessed by Palliative Care Participant Initial Survey, Palliative Care Participant Follow Up Survey, and Feedback Survey. IIa. Increase patient access to quality palliative care in these regions (morphine consumption). IIb. Increase patient access to quality palliative care in these regions (morphine consumption). IIc. Increased patient access to palliative care (PC) measured by the number of patient visits (new and follow-ups). IId. Provider turnover. IIe. Adherence, measured by the number of ECHO sessions held, the number of ECHO participants at each session, and the number of cases reviewed. IIf. Comfort with the ECHO platform and ability to learn/engage via distance technology, assessed by the Palliative Care Participant Initial Survey and Palliative Care Participant Follow Up Survey. OUTLINE: Participants are assigned to 1 of 3 arms. ARM I (ECHO PARTICIPANTS): Participants participate in online ECHO clinics over 1 hour twice monthly for 12 months and in-country workshops twice per year. Participants complete 5 online surveys between baseline through end of year 2 for up to a total of 26 minutes .Participants complete a 15-minute interview in person or phone about their experience in the ECHO project. ARM II (PATIENTS): Patients complete 3 in-person or phone questionnaires over a total of 20 minutes every 3 months for 2 years about their symptoms, emotional and physical well-being, and their experience and satisfaction with outpatient oncology care. Patients' medical charts are reviewed for data collection. Patients complete a 15-minute interview in person or phone about their care received by their physician at baseline, end of month 4 and month 12. ARM III (CAREGIVERS): Caregivers complete an in-person or phone questionnaire over 5 minutes up to 8 times about their experience and satisfaction with the cancer care their family member has received. Caregivers complete a 15 minute interview in person or by phone about the care their family member received by their physician.


Recruitment information / eligibility

Status Recruiting
Enrollment 312
Est. completion date December 31, 2026
Est. primary completion date December 31, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - PATIENT: Scheduled to receive treatment at participating primary care practice for advanced cancer - PATIENT: 18 years or older - PATIENT: Willing to be accessible to the research team for follow-up by telephone or in person - PATIENT: Prognosis of at least 1 year as ascertained by the treating physician - PATIENT: Able to read and understand English as assessed by the treating physician - CAREGIVER: Identified or self-identified as primary caregiver of the patient - CAREGIVER: Willing to be accessible to the research team for follow-up by telephone or in person - CAREGIVER: 18 years or older - CAREGIVER: Able to read and understand English as assessed by the treating physician - ECHO PARTICIPANT: Participant must be a health care provider interested to participate in the study for 2 years and understand the protocol and provide consent - ECHO PARTICIPANT: Able to read and understand English as assessed by principal investigator (PI) Exclusion Criteria: - Unable to understand and sign consent

Study Design


Related Conditions & MeSH terms

  • Advanced Malignant Solid Neoplasm
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Neoplasms

Intervention

Other:
Extension of Community Health (ECHO) Telementoring Clinic
Participate in ECHO clinics presenting cases for guidance and feedback
In-Country Workshops
In-Country Workshops Participate in hands-on training and workshops
Professional Oncology Educations Programs
Receive 5 core online lectures
Medical Chart Review
Medical charts are reviewed for data collection
Questionnaire Administration
Complete questionnaire(s)

Locations

Country Name City State
United States M D Anderson Cancer Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in patients' quality of life Measured by Functional Assessment of Cancer Illness Therapy FACT-General (FACT-G). A 27-item compilation of general questions divided into four primary domains: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, and Functional Well-Being. Each question is assessed using a Likert scale ranging from 0 to 4. The FACT-G total score is the sum of the domain scores.. Baseline up to 12 months
Secondary Change in patients' symptom distress Will be assessed by the Edmonton Symptom Assessment Scale, Symptom Distress Scores, (ESAS-SDS). The ESAS is a validated questionnaire measuring 10 symptoms (pain, fatigue, nausea, depression, anxiety, drowsiness, shortness of breath, appetite, sleep, and well-being). It has good reliability and can be completed within minutes. The ESAS-SDS will be calculated by the sum of the symptom scores of measures ESAS Pain, ESAS Fatigue, ESAS nausea, ESAS Depression, ESAS anxiety, ESAS drowsiness, ESAS Dyspnea, ESAS Appetite, ESAS Well-being. Baseline up to 2 years
Secondary Patients' satisfaction of care Assessed by FAMCARE P16, a self-report scale assessing patient experience and satisfaction with outpatient palliative oncology care, which is composed of 16 items rated from 1 (very dissatisfied) to 5 (very satisfied). The items are not specific for a particular tumor type or symptom but are broadly relevant for outpatients with advanced cancer; the summed items produce a single satisfaction score. Baseline up to 2 years.
Secondary Caregivers' satisfaction of care Assessed by FAMCARE -cg scale, which measures the degree of experience and satisfaction of the caregivers with health care in terms of information provided, availability of care, physical individual with advanced cancer care, and psychological care for patients. Baseline up to 2 years
Secondary Providers' efficacy in knowledge of delivering palliative care Assessed by completing the Palliative Care Participant Initial Survey Baseline
Secondary Providers' efficacy in knowledge of delivering palliative care Assessed by completing the Palliative Care Participant Follow up Survey composed of 9 questions about providers' knowledge of assessments performed in the palliative care setting. Up to 2 years
Secondary Providers' competence to deliver palliative care Measured by the distance technology sessions held twice monthly. Baseline up to 2 years
Secondary Providers' Satisfaction and feedback Assessed by completing 7 questions about providers' opinions of distance learning technology. Baseline up to 2 years
Secondary Burnout among ECHO participant Measured by Maslach Burnout Inventory-Human Services Survey (MBI-HSS). It consists of three factors (depersonalization [DP], emotional exhaustion [EE], and personal achievement [PA]) with 22 items, each scored on a 7-point Likert scale. DP and EE scores are positively correlated with burnout, while PA is negatively correlated. Baseline up to 2 years
See also
  Status Clinical Trial Phase
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT05106374 - Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer
Recruiting NCT05660421 - Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors Phase 2
Suspended NCT04060849 - Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY Phase 1
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Withdrawn NCT04127721 - Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation Phase 2
Active, not recruiting NCT03712878 - 2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies Phase 2
Active, not recruiting NCT06062901 - An Educational Intervention on Provider Knowledge for the Support of Cancer Survivors N/A
Terminated NCT04081298 - eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors N/A
Completed NCT04983901 - PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN Phase 2
Recruiting NCT04188912 - Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study
Active, not recruiting NCT04592250 - Financial Toxicity in Cancer Patients
Recruiting NCT05112614 - Role of Gut Microbiome in Cancer Therapy
Active, not recruiting NCT04296305 - Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain Phase 4
Withdrawn NCT04190433 - Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial Phase 2
Terminated NCT04083170 - Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers Phase 2
Recruiting NCT02464696 - Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure N/A
Withdrawn NCT04820894 - Perception of Cure Among Patients With Metastatic Cancer
Completed NCT03125070 - Self-Management Program and Survivorship Care Plan in Improving the Health of Cancer Survivors After Stem Cell Transplant Phase 3
Completed NCT01664910 - CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies Phase 1/Phase 2